EE200300559A - Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks - Google Patents
Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseksInfo
- Publication number
- EE200300559A EE200300559A EEP200300559A EEP200300559A EE200300559A EE 200300559 A EE200300559 A EE 200300559A EE P200300559 A EEP200300559 A EE P200300559A EE P200300559 A EEP200300559 A EE P200300559A EE 200300559 A EE200300559 A EE 200300559A
- Authority
- EE
- Estonia
- Prior art keywords
- osteopontin
- prevention
- treatment
- neurological disorders
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111296 | 2001-05-17 | ||
PCT/EP2002/005081 WO2002092122A2 (en) | 2001-05-17 | 2002-05-08 | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200300559A true EE200300559A (et) | 2004-02-16 |
Family
ID=8177366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300559A EE200300559A (et) | 2001-05-17 | 2002-05-08 | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks |
Country Status (27)
Country | Link |
---|---|
US (4) | US7217687B2 (xx) |
EP (1) | EP1389130B1 (xx) |
JP (2) | JP4417632B2 (xx) |
KR (1) | KR100947424B1 (xx) |
CN (2) | CN1286524C (xx) |
AT (1) | ATE555803T1 (xx) |
AU (1) | AU2002312886B2 (xx) |
BG (1) | BG108337A (xx) |
BR (1) | BR0209812A (xx) |
CA (1) | CA2443964A1 (xx) |
CZ (1) | CZ20033109A3 (xx) |
EA (1) | EA006655B1 (xx) |
EE (1) | EE200300559A (xx) |
ES (1) | ES2387082T3 (xx) |
HK (1) | HK1067051A1 (xx) |
HR (1) | HRP20030840A2 (xx) |
HU (1) | HUP0400005A3 (xx) |
IL (2) | IL158867A0 (xx) |
MX (1) | MXPA03010327A (xx) |
NO (1) | NO20035025D0 (xx) |
NZ (1) | NZ528852A (xx) |
PL (1) | PL211763B1 (xx) |
SK (1) | SK14232003A3 (xx) |
UA (1) | UA85368C2 (xx) |
WO (1) | WO2002092122A2 (xx) |
YU (1) | YU89503A (xx) |
ZA (1) | ZA200307956B (xx) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046719A1 (en) * | 2003-11-12 | 2005-05-26 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
WO2002090974A2 (de) * | 2001-05-09 | 2002-11-14 | Biovision Ag | Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien |
AU2002357748A1 (en) | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
CA2489905A1 (en) * | 2002-06-25 | 2003-12-31 | Aventis Pharmaceuticals Inc. | Osteopontin, oligodendrocytes and myelination |
WO2004013311A2 (en) * | 2002-08-06 | 2004-02-12 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
KR20050119149A (ko) * | 2003-03-28 | 2005-12-20 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 말초 신경 질환의 치료 및/또는 예방을 위한 클루스테린의용도 |
RU2379975C2 (ru) * | 2003-09-18 | 2010-01-27 | Арла Фудс Амба | Добавка в состав для детского питания |
US7790687B2 (en) * | 2005-02-18 | 2010-09-07 | Proximagen Ltd. | Treatment for neurodegeneration |
US20060264371A1 (en) * | 2005-02-18 | 2006-11-23 | Proximagen Ltd. | Treatment |
WO2007047465A1 (en) | 2005-10-13 | 2007-04-26 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
WO2008086449A2 (en) * | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
US20100069254A1 (en) * | 2008-09-16 | 2010-03-18 | Laree Hiser | Cell Culture Model for Demyelination/Remyelination |
KR101449100B1 (ko) | 2011-04-21 | 2014-10-13 | 가톨릭대학교 산학협력단 | 신경세포 데브리스 제거용 오스테오폰틴 |
GB2493540A (en) * | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
KR101728808B1 (ko) * | 2012-09-28 | 2017-04-20 | 한국생명공학연구원 | 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2016033329A1 (en) * | 2014-08-27 | 2016-03-03 | Dana-Farber Cancer Institute, Inc. | Intracellular osteopontin regulates the lineage commitment of lymphoid subsets |
KR102425326B1 (ko) | 2016-05-20 | 2022-07-25 | 세다르스-신나이 메디칼 센터 | 알츠하이머병 및 관련 병태의 치료 또는 예방 방법 |
CN109996810B (zh) * | 2016-11-27 | 2023-08-22 | 特里同阿盖亚创新公司 | 从微藻中纯化重组骨桥蛋白的方法 |
WO2018202870A1 (en) | 2017-05-04 | 2018-11-08 | Follicum Ab | Peptides for treatment of diabetes |
US11484576B2 (en) | 2017-08-15 | 2022-11-01 | The Children's Medical Center Corporation | Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment |
TR201903865A2 (tr) * | 2019-03-14 | 2020-09-21 | Bogazici Ueniversitesi | Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi |
WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
CN111388654A (zh) * | 2020-05-22 | 2020-07-10 | 南通大学 | 治疗脊髓损伤的药物、药物试剂盒及方法 |
EP4159223A1 (en) * | 2020-06-02 | 2023-04-05 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Composition comprising osteopontin inhibitor as active ingredient for prevention, alleviation, or treatment of neurodegenerative disease |
CN117720620A (zh) * | 2023-12-13 | 2024-03-19 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69926536T3 (de) * | 1998-12-22 | 2013-09-12 | Genentech, Inc. | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
JP2003517284A (ja) | 1999-04-15 | 2003-05-27 | チルドレンズ メディカル センター コーポレーション | 免疫応答を変調する方法及び組成物 |
WO2000064460A2 (en) | 1999-04-23 | 2000-11-02 | Sulzer Orthopedics Ltd. | Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin |
JP4027663B2 (ja) * | 1999-10-04 | 2007-12-26 | ネクター セラピューティックス エイエル,コーポレイション | ポリマー安定化神経ペプチド |
-
2002
- 2002-05-08 CA CA002443964A patent/CA2443964A1/en not_active Abandoned
- 2002-05-08 SK SK1423-2003A patent/SK14232003A3/sk unknown
- 2002-05-08 AU AU2002312886A patent/AU2002312886B2/en not_active Ceased
- 2002-05-08 EE EEP200300559A patent/EE200300559A/xx unknown
- 2002-05-08 EP EP02738042A patent/EP1389130B1/en not_active Expired - Lifetime
- 2002-05-08 EA EA200301253A patent/EA006655B1/ru not_active IP Right Cessation
- 2002-05-08 US US10/477,876 patent/US7217687B2/en not_active Expired - Fee Related
- 2002-05-08 HU HU0400005A patent/HUP0400005A3/hu unknown
- 2002-05-08 PL PL367065A patent/PL211763B1/pl not_active IP Right Cessation
- 2002-05-08 AT AT02738042T patent/ATE555803T1/de active
- 2002-05-08 MX MXPA03010327A patent/MXPA03010327A/es active IP Right Grant
- 2002-05-08 WO PCT/EP2002/005081 patent/WO2002092122A2/en active Application Filing
- 2002-05-08 CN CNB028144627A patent/CN1286524C/zh not_active Expired - Fee Related
- 2002-05-08 KR KR1020037014773A patent/KR100947424B1/ko not_active IP Right Cessation
- 2002-05-08 CN CNA2006101317669A patent/CN1939538A/zh active Pending
- 2002-05-08 CZ CZ20033109A patent/CZ20033109A3/cs unknown
- 2002-05-08 ES ES02738042T patent/ES2387082T3/es not_active Expired - Lifetime
- 2002-05-08 JP JP2002589038A patent/JP4417632B2/ja not_active Expired - Fee Related
- 2002-05-08 NZ NZ528852A patent/NZ528852A/en not_active IP Right Cessation
- 2002-05-08 YU YU89503A patent/YU89503A/sh unknown
- 2002-05-08 BR BR0209812-1A patent/BR0209812A/pt not_active IP Right Cessation
- 2002-05-08 IL IL15886702A patent/IL158867A0/xx unknown
- 2002-05-08 UA UA20031110269A patent/UA85368C2/ru unknown
-
2003
- 2003-10-13 ZA ZA200307956A patent/ZA200307956B/en unknown
- 2003-10-15 HR HR20030840A patent/HRP20030840A2/hr not_active Application Discontinuation
- 2003-11-10 BG BG108337A patent/BG108337A/bg unknown
- 2003-11-12 NO NO20035025A patent/NO20035025D0/no not_active Application Discontinuation
- 2003-11-13 IL IL158867A patent/IL158867A/en not_active IP Right Cessation
-
2004
- 2004-11-05 US US10/981,737 patent/US7297099B2/en not_active Expired - Fee Related
- 2004-12-22 HK HK04110138A patent/HK1067051A1/xx not_active IP Right Cessation
-
2007
- 2007-02-27 US US11/679,735 patent/US20070225214A1/en not_active Abandoned
- 2007-11-07 US US11/936,623 patent/US20080213234A1/en not_active Abandoned
-
2009
- 2009-06-05 JP JP2009136621A patent/JP5036761B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300559A (et) | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks | |
NO20034056D0 (no) | Proliferative sykdommer | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
NO20043237L (no) | Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
MY124786A (en) | Bis-arylsulfones | |
UA96926C2 (ru) | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
NO20033803D0 (no) | Karbamat for behandling av bevegelseslidelser | |
EE200400005A (et) | Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine | |
HRP20031057B1 (hr) | Tableta koja sadrži cetirizin i pseudoefedrin | |
IL181713A0 (en) | Use of il-17f for the treatment and/or prevention of neurological diseases | |
AU2002354698A1 (en) | Use of xaa-pro peptidases for the treatment of substance p-related disorders | |
WO2004112690A3 (en) | 2-aminobenzoyl derivatives | |
EE200200670A (et) | S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks | |
BR0210678A (pt) | Carbamatos de 2-heterocìclicos-1,2-etanodióis | |
WO2003064394A8 (de) | 5-ring heterozyklen zur verwendung als antiviral mittel | |
DK1133297T3 (da) | Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin | |
DE60115831D1 (de) | Gugulipid zur Behandlung von kognitiven Störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB1A | Change in the ownership or in the address of the owner | ||
HC1A | Change of owner name |